At SABCS 2025, studies show some patients with early-stage breast cancer can skip steps like SLNB or MRI without...
Receiving a cancer diagnosis often means navigating numbers, such as estimates of the chance of recurrence. But cancer patients...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx)...
Three years ago, the American Association for Cancer Research (AACR) launched this blog with a welcome post from Chief...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today Nearly 1.7 million new cancer cases and roughly 600,000...
The American Association for Cancer Research (AACR) has appeared in numerous publications lately, showcasing the breadth of our mission...
recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib...
Prevention is often said to be more powerful than a cure. With an eye toward thwarting the disease, some...
As spring is a time for flowers to bloom, public education at the American Association for Cancer Research (AACR)...
The American Association for Cancer Research (AACR) wrapped up National Cancer Research Month by inviting a group of 50...